Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Aug;257(2 Pt 2):H395-8.
doi: 10.1152/ajpheart.1989.257.2.H395.

Calf sweat lactate in peripheral arterial occlusive disease

Affiliations
Clinical Trial

Calf sweat lactate in peripheral arterial occlusive disease

N Fellmann et al. Am J Physiol. 1989 Aug.

Abstract

The energy metabolism of sweat glands was studied to evaluate the reduction in oxygen delivery in the tissue of patients with peripheral arterial occlusive disease. We compared lactate concentration in pilocarpine-iontophoresis sweat collected from the middle calf area ([ L]sw) of 10 healthy subjects (group 1) and 84 patients suffering from intermittent claudications (group 2, n = 49), from rest pain (group 3, n = 21), and from severe ischemic skin changes (group 4, n = 14). In addition, the effect of a vasoactive drug (naftidrofuryl, 600 mg) or placebo infusion on [L]sw was investigated (n = 30). Results (means +/- SE) showed that 1) [L]sw (mmol/l) increased significantly with the severity of the symptoms: group 1 = 16.5 +/- 0.4, group 2 = 18.7 +/- 0.4, group 3 = 22.8 +/- 0.9, and group 4 = 27.5 +/- 2.0; and 2) [L]sw was reduced by 10% (P less than 0.01) after naftidrofuryl infusion, whereas there was no change after placebo infusion. We suggest that lactate in calf sweat is a good indicator in the evaluation of the severity of peripheral occlusive arterial disease and in assessing the efficiency of vasoactive drug treatment.

PubMed Disclaimer

Publication types

LinkOut - more resources